Walter Capone
Vorstandsvorsitzender bei CAEREGEN THERAPEUTICS, LLC
Profil
Walter M.
Capone is currently the President & Chief Executive Officer at Caeregen Therapeutics LLC.
Previously, he held positions such as Director-Infectious Diseases & Immunology at Bristol-Myers Squibb World Wide Medicines Group, Vice President-Marketing & Product Development at Triangle Pharmaceuticals, Inc., and VP-Commercial Development & Operations at Progenics Pharmaceuticals, Inc. He was also the Senior Vice President-Commercial Operations at Trimeris, Inc. from 2002 to 2007.
In addition, he served as the Chief Business Officer at GeneCentric Therapeutics, Inc. from 2017 to 2021.
He has also worked as a Venture Partner at Boston Millennia Partners and as the Chief Financial Officer & VP-Commercial Operations at TherapyEdge, Inc. Furthermore, he was the President of The Multiple Myeloma Research Foundation, Inc. from 2013 to 2014.
Mr. Capone received his undergraduate degree from Brown University and his MBA from Columbia Business School.
Aktive Positionen von Walter Capone
| Unternehmen | Position | Beginn |
|---|---|---|
| CAEREGEN THERAPEUTICS, LLC | Vorstandsvorsitzender | 01.09.2022 |
Ehemalige bekannte Positionen von Walter Capone
| Unternehmen | Position | Ende |
|---|---|---|
GeneCentric Therapeutics, Inc.
 GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Corporate Officer/Principal | 03.02.2021 |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01.01.2007 |
Boston Millennia Partners
 Boston Millennia Partners Investment ManagersFinance Boston Millennia Partners (BMP) is a private equity and venture capital subsidiary of Glen Ventures Management, Inc founded in 1997 by Dana Callow. The firm headquartered in Boston, Massachusetts. | Private Equity Investor | - |
The Multiple Myeloma Research Foundation, Inc.
 The Multiple Myeloma Research Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Multiple Myeloma Research Foundation, Inc. provides funding for research on myeloma treatment. It provides funding to laboratories worldwide, including compounds and approaches in clinical trials and pre-clinical studies. The firm also facilitates clinical trials through their affiliate organization, the Multiple Myeloma Research Consortium. The company was founded by Karen E. Andrews and Kathryn E. Giusti in 1998 and is headquartered in Norwalk, CT. | Vorstandsvorsitzender | - |
Bristol-Myers Squibb World Wide Medicines Group
 Bristol-Myers Squibb World Wide Medicines Group Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb World Wide Medicines Group manufactures pharmaceutical products. The company is based in Lawrenceville, NJ. | Corporate Officer/Principal | - |
Ausbildung von Walter Capone
| Brown University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Triangle Pharmaceuticals, Inc.
 Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Triangle Pharmaceuticals Inc. provided antiviral drug candidates for the human immunodeficiency virus. The company was founded in 1995 and was located in Durham, NC. | Commercial Services |
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Health Technology |
Boston Millennia Partners
Boston Millennia Partners Investment ManagersFinance Boston Millennia Partners (BMP) is a private equity and venture capital subsidiary of Glen Ventures Management, Inc founded in 1997 by Dana Callow. The firm headquartered in Boston, Massachusetts. | Finance |
TherapyEdge, Inc.
 TherapyEdge, Inc. Internet Software/ServicesTechnology Services Part of Advanced Biological Laboratories SA, TherapyEdge, Inc. provides a database for HIV patient's clinical records. The company is based in Durham, NC. TherapyEdge was acquired by Advanced Biological Laboratories SA on February 14, 2005. | Technology Services |
The Multiple Myeloma Research Foundation, Inc.
The Multiple Myeloma Research Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Multiple Myeloma Research Foundation, Inc. provides funding for research on myeloma treatment. It provides funding to laboratories worldwide, including compounds and approaches in clinical trials and pre-clinical studies. The firm also facilitates clinical trials through their affiliate organization, the Multiple Myeloma Research Consortium. The company was founded by Karen E. Andrews and Kathryn E. Giusti in 1998 and is headquartered in Norwalk, CT. | Commercial Services |
Bristol-Myers Squibb World Wide Medicines Group
Bristol-Myers Squibb World Wide Medicines Group Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb World Wide Medicines Group manufactures pharmaceutical products. The company is based in Lawrenceville, NJ. | Health Technology |
| CAEREGEN THERAPEUTICS, LLC |
